Cancer Treatment Denial Appeals: A Complete Guide

A cancer diagnosis is overwhelming. A coverage denial on top of it can feel like a devastating blow. But cancer treatment denials — for chemotherapy, immunotherapy, targeted therapy, radiation, or surgical procedures — are frequently overturned on appeal. Time is critical. This guide gives you the fastest, most effective path to fighting back.

The Most Common Cancer Denial Types

  • Prior authorization denied: Your insurer requires pre-approval for chemotherapy, immunotherapy, or major cancer surgery, and that approval was denied or revoked.
  • "Experimental or investigational" treatment: Your insurer classifies the treatment as experimental, even if your oncologist and major oncology guidelines consider it the standard of care.
  • Off-label drug use: Your oncologist prescribed a chemotherapy agent or targeted therapy for a cancer type not included on the drug's FDA-approved label. Many highly effective cancer treatments are used off-label.
  • Clinical trial routine care costs: Your insurer refuses to cover the standard care costs (labs, imaging, clinic visits) associated with participating in a clinical trial.
  • Specialist or facility out-of-network: The best oncologist or cancer center for your condition is out of your insurer's network.

Request an Expedited Appeal Immediately

For cancer treatment denials, do not wait for the standard review timeline. Request an expedited (urgent) appeal immediately. Your oncologist can certify that following the standard 30–60 day timeline would seriously jeopardize your health — this is almost always true for active cancer treatment denials.

Under federal law, expedited internal appeals must be decided within 72 hours. Expedited external reviews also have a 72-hour deadline. This is your fastest path to a decision.

Review the full appeal process guide to understand the standard vs. expedited timelines and when each applies.

Building Your Appeal: The Essential Documents

A cancer treatment appeal lives or dies on the quality of its documentation. You need:

  1. Your oncologist's Letter of Medical Necessity. This must be detailed, specific, and address the insurer's stated denial reason head-on. See our medical necessity letter guide. The letter should include: your diagnosis (cancer type, stage, molecular markers), prior treatments tried and their outcomes, and why the denied treatment is the appropriate standard of care.
  2. NCCN Clinical Practice Guidelines. Download the relevant NCCN guideline for your cancer type from nccn.org and highlight the section that recommends the denied treatment for your specific cancer stage and molecular profile. This is extraordinarily powerful evidence — NCCN guidelines are the gold standard for oncology care.
  3. ASCO or other specialty society guidelines. The American Society of Clinical Oncology (ASCO) and other oncology bodies publish evidence-based treatment guidelines that support the standard of care.
  4. Peer-reviewed clinical studies. Ask your oncologist to identify key clinical trials (phase 2 or 3) that established the denied treatment as effective for your cancer type.
  5. Pathology reports and imaging. Include your most recent diagnostic workup to establish your exact diagnosis, stage, and biomarker profile.

Addressing the "Experimental" Denial

The "experimental or investigational" denial is the most legally complex cancer appeal. Your argument must counter the insurer's definition of "experimental" with evidence that the treatment is the accepted standard of care.

Most insurer plan documents define a treatment as experimental if it lacks "widely accepted clinical evidence" or "general acceptance" in the medical community. The NCCN guidelines directly establish general acceptance. If the NCCN guidelines recommend Category 1 (based on high-level evidence with uniform NCCN consensus) or Category 2A (based on lower-level evidence with uniform consensus), the treatment is clearly not experimental.

For experimental treatment denials more broadly, see our targeted guide on this denial type.

External Review: Your Most Powerful Tool for Cancer Denials

If your internal appeal is denied, go immediately to Independent External Review. Cancer treatment denials — particularly experimental treatment claims — have some of the highest external review overturn rates of any claim type. Independent oncology reviewers evaluate cases based on current medical evidence and oncology guidelines, not the insurer's internal cost criteria.

Request an expedited external review (72 hours) for any active treatment denial. Include all the documentation from your internal appeal and your oncologist's updated letter if any new information is available.

Frequently Asked Questions

Can an insurer deny cancer treatment as "experimental"?
Yes, but this is one of the most contested and legally complex denial types. If your insurer denies a cancer treatment as experimental, the appeal must include peer-reviewed medical literature, oncology society guidelines (ASCO, NCCN), and your oncologist's letter explaining that the treatment meets the current standard of care for your specific cancer type and stage. Many "experimental" denials are overturned at external review.
What is an expedited appeal and do I qualify if I have cancer?
An expedited appeal is a fast-track review that requires a decision within 72 hours (for internal appeals) or 72 hours (for external reviews). To qualify, your physician must certify that following the standard timeline would seriously jeopardize your life or health. Most active cancer treatment denials qualify for expedited review — your oncologist should have no hesitation certifying urgency.
What is the NCCN and how does it help cancer treatment appeals?
The National Comprehensive Cancer Network (NCCN) publishes evidence-based clinical practice guidelines for every major cancer type. These guidelines define what constitutes the standard of care for each cancer at each stage. Including the relevant NCCN guideline recommendation in your appeal is extremely powerful — insurers have difficulty denying treatment that NCCN explicitly recommends.
Are clinical trial costs covered by insurance?
Under the ACA, most insurance plans must cover routine costs of patient care during an approved clinical trial (costs like labs, imaging, and standard visits). The experimental intervention itself is typically paid by the trial sponsor, not the insurer. If your insurer is denying routine care costs related to a clinical trial, appeal citing the ACA clinical trial provisions.

Continue Your Research